Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021, Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options, Why Bionano Genomics (BNGO) Might Surprise This Earnings Season, Bionano Customer Praxis Genomics Receives DEX Z-Codes from Palmetto for their Whole Genome Analysis LDT on Saphyr, Bionano Genomics to Present at the Cowen 41st Annual Health Care Conference, Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know, Bionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer, Bionanos Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed, Analyst Pounds the Table on Bionano (BNGO) Stock, Analyzing Bionano Genomics's Unusual Options Activity. The presentations will cover applications of optical genome mapping (OGM) with Saphyr to analyze the genomes of patients with a variety of genetic diseases, blood cancers, solid tumors and repeat disorders as well as the studies supporting validation of clinical assays developed by Saphyr users. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Find the latest Institutional Holdings data for Bionano Genomics, Inc. Common Stock (BNGO) at Nasdaq.com. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. Bionano Genomics, Inc. (BNGO) Gains As Market Dips: What You Should Know, Largest Hospital Diagnostic Lab in Canada Pilots Bionanos Saphyr; Seeking to Convert 30-Year-Old Workflow Based on Multiple Technologies Into a Single, High-Resolution Assay to Transform Cancer Diagnosis, Bionano Stock Gets a New Street-High Price Target, 3 Stocks That Turned $200,000 Into $1 Million (or More) in 3 Months, Presentation Recordings from Bionanos Next-Generation Cytogenomics Symposium, its Most Attended Event to Date, Now Available Online, Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know, Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research, Dr. Gordana Raca from Childrens Hospital Los Angeles Presents Findings That Show Saphyr Detects Druggable Gene Fusions in Pediatric Acute Leukemias that NGS and Cytogenetics Missed, Bionano Chief Medical Officer Presents Vision for Optical Genome Mapping as a First Line Clinical Tool for Cancer and Genetic Disease Testing at Festival of Genomics & Biodata, Bionano Significantly Reduces Analysis Cost and Time to Actionable Results with Update to its Cloud Compute, 3 Electric Stocks That Turned $100,000 Into $1 Million in 6 Months, Why Bionano Genomics Stock Rocketed More Than 28% Today, Is Bionano Stock Still Worth Buying After Its 2,300%-Plus Rally? The event is being held virtually and concludes on January 15, 2021. Bionano Genomics, Inc. Additional speakers show how Saphyr can find pathogenic variants undetected by traditional methods for a variety of genetic diseases and disorders of sex development.Tuesday, January 12: Heme MalignancyEight speakers from around the world will present results from their studies comparing Saphyr with the cytogenetic standard of care for genome analysis of a variety of heme malignancies including MDS, adult and pediatric B-ALL, and CLL leukemias, ending with the presentation of results from a large national multi-center evaluation on Acute Myeloid Leukemia.Wednesday, January 13: Solid TumorIn this session, speakers will discuss their analysis of solid tumor genome structure in head and neck cancer, non-inflammatory and inflammatory breast cancer, liver cancer, uveal melanoma, ending with an update on the development of a cancer LDT with Saphyr.Thursday, January 14: Complex Molecular DiagnosticsThis session returns to genetic diseases with a focus on repeat expansions and contractions and other complex molecular mechanisms. Bionano Genomics Announces Positive Outcome of Its Special Stockholder Meeting, Bionano Genomics Announces Continued Expansion of Global Business with Adoption of Saphyr for Next-Generation Cytogenomics in Eastern Europe and Australia, German Accreditation of Laboratory Developed Tests on Bionanos Saphyr System Accelerates Utilization in Clinical Diagnostics, BioNano Genomics Stock Is Dashing Towards a Brighter Future, Says Analyst, Bionano to Present at the September 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Bionano Data Provides Understanding of Repeat Expansion Disorders Causing Muscular Dystrophy and ALS, Bionano Genomics Continues to See Expansion in the Adoption of Saphyr for Digital Cytogenetics at Leading Medical Institutions, Bionano Genomics Expands Its Diagnostic Testing Menu with Launch of Lineagens EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions Related to Epilepsy, Bionano Genomics Announces Continued Expansion of European Business With Adoption of Saphyr at Three of Europes Largest Pediatric Hospitals in Spain, Italy and France, Vertebrate Genome Project Rules Bionano Optical Mapping Technology As Essential Part of Assembling Reference Quality Genomes, Bionano Genomics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), Independent Proxy Advisory Firm ISS Recommends Bionano Stockholders Vote FOR Authorized Shares Increase Proposal. ​Friday, January 15: Covid-19 Host Genome SV Expert Panel SessionKey members of the COVID-19 Host Genome SV Consortium will present how they are using Saphyr and other genomics technologies to detect structural variants in the human genome that can predispose to mild or severe COVID-19 disease. The last day of the symposium is dedicated to the study of the genomes of severely ill COVID-19 patients. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Analyst Weighs In, Bionano Genomics Announces Closing of $230 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares, Bionano Genomics' stock rally result of awareness push in 2019 and 2020 about its genomic technology: analyst, UPDATE: Bionano Genomics prices $200 million underwritten stock offering at a discount of $6 a share, Bionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock, Bionano Genomics to sell more shares, stock falls, Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock, MD Anderson Cancer Center Publication Shows How Bionanos Saphyr System Can Significantly Reduce Time to Actionable Results for Myelodysplastic Syndrome Patients, Day Five of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness, Day Four of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Solves Genetic Mysteries, Enables Study of Complex Genetic Diseases, Simplifies Muscular Dystrophy Testing, Day Three of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Provides Complete Structural Variation Analysis in Solid Tumors, Enables Discovery of Novel Diagnostic Markers and Drug Targets, Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement, Day Two of Bionanos Next-Generation Cytogenomics Symposium: Saphyr Outperforms Standard Cytogenetics in Heme Malignancies, is Less Expensive, Provides Actionable Information Faster, in Single Assay, Bionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares, Day One of Bionanos Next-Generation Cytogenomics Symposium: Customer Progress in Applications Development in Prenatal Testing, Validation Against Traditional Cytogenetics and Resolution for Undiagnosed Patients, COVID-19 Host Genome SV Consortium Identifies Structural Variants with Possible Roles in Pathogenesis and Outcomes in Severely Ill COVID-19 Patients Using Bionanos Saphyr® System, Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyrs Utility in Genome Analysis for Genetic Disease and Cancer, Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share, Bionano Genomics Announces Pricing of $88.5 Million Underwritten Public Offering of Common Stock, Bionano Genomics shares fall after plan to sell more stock, The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data, Why Bionano Genomics Stock Skyrocketed More Than 100% Today, Return On Capital Employed Overview: Bionano Genomics, Bionano Genomics Publishes Study on Autism Risk Genes After Detailed Analysis of The Genome of Professor Temple Grandin, Who Has Brought Awareness to Autism Spectrum Disorder Through Her Activism, Bionanos Genome Mapping Platform Could Be a Game Changer, Says Analyst, Bionano Genomics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule, Bionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that Uses Whole Genome Analysis with Saphyr as Alternative to Chromosomal Microarray and Karyotyping, BioNano Genomics: Set to Execute in 2021, Says Analyst, Publication Reveals in Side-by-Side Comparison that Method Using PacBio Sequencing Detects Only 72% of the Large Structural Variants Detected by Optical Genome Mapping with Saphyr, Bionano Genomics Achieves Key Milestone with Software Update for its Saphyr System that Increases Throughput to 96 Human Genomes Per Week and Adds Saphyr Assure for Monitoring System Health, Bionanos Saphyr System Used to Characterize Virus Integration Into Human Genome, Bionano Genomics Users Present the Saphyr System As a Novel Diagnostic Tool for Hematological Malignancies at ASH 2020, Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020, Is Now the Time to Pull the Trigger on Bionano Stock?
Fashion Documentaries Netflix Australia, Tv Writer Assistant Jobs, Fashion Documentaries Netflix Australia, Where Is Chris Whitty, Horror Host Tv Tropes, Psg Vs Manchester United Results,